Observational studyJournal of the American Heart Association2026
Association Between Monoclonal Gammopathy of Undetermined Significance and Cardiovascular Disease Risk: A Veterans Health Administration Study.
Observational study in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Unmasking the Hidden Burden: Inflammation and Cardiovascular DiseaseJournal of the American Heart Association · 2026Article
- Differential life expectancies and life years lost associated with multiple myeloma in the United States: a simulation modeling study.The oncologist · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMonoclonal gammopathy of undetermined significance (MGUS) is associated with an increased risk of cardiovascular disease (CVD). However, its potential to provide additional prognostic information beyond traditional CVD risk assessments remains unknown. This study aimed to examine the association between MGUS and incident CVD and to determine whether MGUS status offers additional prognostic value beyond the established atherosclerotic cardiovascular disease risk calculation.
methodsWe conducted a retrospective, matched observational study using 2010 to 2021 Veterans Health Administration data. MGUS status, confirmed through a validated natural language processing algorithm, were 1:5 matched to individuals without MGUS. The outcome of interest was an incident CVD event. Cumulative incidence functions were compared using Gray's test. Multivariable Fine and Gray's subdistribution models were performed to estimate the adjusted hazard ratios (aHRs) for incident CVD. Analyses were also stratified by atherosclerotic CVD risk category (low/borderline, intermediate, high).
resultsThe analytic cohort included 70 320 individuals (11 720/58 600 with/without MGUS); MGUS was associated with a higher 10-year CVD incidence (29.5% versus 9.7%;
conclusionsMGUS is an independent risk factor of incident CVD across all atherosclerotic CVD risk categories in a heterogeneous cohort of US veterans. These findings underscore the connection between the immune system and CVD and suggest that determination of MGUS status is of clinical utility in adults at risk for CVD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.